TCR therapeutics for non-HLA-A*02 patients
Today's T-cell-receptor drugs only work for people with one tissue type. Building versions for the other common types would roughly double who can be treated.
Tebentafusp and brenetafusp require HLA-A*02:01. Immunocore and others have preclinical ImmTACs against PRAME on HLA-A*24 and A*11, common in East Asian populations.
Pages like this
not linked directly; found by shared links- TrialPRISM-MEL-301
Shares Brenetafusp, PRAME, T-cell engagers (bispecific), Melanoma.
- CompanyImmunocore
Shares Brenetafusp, PRAME, Tebentafusp, Melanoma.
- Targetgp100 (PMEL)
Shares Tebentafusp, TCR-T cell therapy, T-cell engagers (bispecific), Melanoma.
- CompanyImmatics
Shares PRAME, TCR-T cell therapy, Melanoma.
- TrialIMCgp100-202
Shares Tebentafusp, T-cell engagers (bispecific), Melanoma.
- CancerUveal melanoma
Shares Brenetafusp, HLA-A*02:01 restriction, PRAME, Tebentafusp.
- IdeaAntibodies that see mutant KRAS and p53 fragments displayed on the cell surface
Shares Tebentafusp, TCR-T cell therapy, T-cell engagers (bispecific).
- InstitutionOxford Cancer – Oxford University Hospitals and University of Oxford
Shares Tebentafusp, T-cell engagers (bispecific), Melanoma.